Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Helen M. Colhoun, Ildiko Lingvay, Paul Brown, et al.
Nature Medicine (2024) Vol. 30, Iss. 7, pp. 2058-2066
Open Access | Times Cited: 62

Showing 1-25 of 62 citing articles:

Semaglutide in patients with overweight or obesity and chronic kidney disease without diabetes: a randomized double-blind placebo-controlled clinical trial
Ellen M. Apperloo, José Luis Górriz, María José Soler, et al.
Nature Medicine (2024)
Closed Access | Times Cited: 18
KDOQI US Commentary on the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of CKD
Sankar D. Navaneethan, Nisha Bansal, Kerri L. Cavanaugh, et al.
American Journal of Kidney Diseases (2024)
Closed Access | Times Cited: 17
Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes
Areesha Moiz, Kristian B. Filion, Helia Toutounchi, et al.
Annals of Internal Medicine (2025) Vol. 178, Iss. 2, pp. 199-217
Closed Access | Times Cited: 7
How ‘miracle’ weight‐loss semaglutide promises to change medicine but can we afford the expense?
Ralf Weiskirchen, Amedeo Lonardo
British Journal of Pharmacology (2025)
Open Access | Times Cited: 3
Glucagon like peptide-1 (GLP-1) agonists and cardiometabolic protection: historical development and future challenges
Francisco Westermeier, Enrique Z. Fisman
Cardiovascular Diabetology (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD Practice Guidance
Vincent Chen, Timothy R. Morgan, Yaron Rotman, et al.
Hepatology (2024)
Open Access | Times Cited: 15
Lupus nephritis-related chronic kidney disease
Julia Lichtnekert, Hans‐Joachim Anders
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 11, pp. 699-711
Closed Access | Times Cited: 12
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials
Sunil V. Badve, Anika Bilal, Matthew M.Y. Lee, et al.
The Lancet Diabetes & Endocrinology (2024)
Closed Access | Times Cited: 11
Kidney and Cardiovascular Outcomes Among Patients With CKD Receiving GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of Randomized Trials
Jui‐Yi Chen, Tsuen‐Wei Hsu, Jung-Hua Liu, et al.
American Journal of Kidney Diseases (2025)
Open Access | Times Cited: 1
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions
Naveed Sattar, Matthew M.Y. Lee
The Lancet Diabetes & Endocrinology (2025)
Closed Access | Times Cited: 1
Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities
Clifford J. Bailey, Peter R. Flatt, J. Michael Conlon
Peptides (2025) Vol. 187, pp. 171380-171380
Open Access | Times Cited: 1
Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT)
Subodh Verma, Helen M. Colhoun, Dror Dicker, et al.
Journal of the American College of Cardiology (2024) Vol. 84, Iss. 17, pp. 1678-1682
Open Access | Times Cited: 7
GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined Therapy
André Scheen
Drugs (2024)
Closed Access | Times Cited: 7
ASN Kidney Health Guidance on the Management of Obesity in Persons Living with Kidney Diseases
T. Alp İkizler, Holly Kramer, Srinivasan Beddhu, et al.
Journal of the American Society of Nephrology (2024) Vol. 35, Iss. 11, pp. 1574-1588
Closed Access | Times Cited: 4
The Future of Glucagon-Like Peptide-1 Receptor Agonists In Cardiovascular–Kidney–Metabolic Diseases
Matias Trillini, Trond Jenssen, William P. Martin, et al.
Nephrology Dialysis Transplantation (2025)
Closed Access
Risk-directed management of chronic kidney disease
Matthew F. Blum, Brendon L. Neuen, Morgan E. Grams
Nature Reviews Nephrology (2025)
Closed Access
Generalizability of SELECT to Cardiac Surgical Patients
Nitish K. Dhingra, Raj Verma, C. David Mazer, et al.
JACC Advances (2025) Vol. 4, Iss. 3, pp. 101597-101597
Closed Access
THE PREVENTION AND MANAGEMENT OF CHRONIC KIDNEY DISEASE AMONG PATIENTS WITH METABOLIC SYNDROME
Doreen Zhu, Parminder K. Judge, Christoph Wanner, et al.
Kidney International (2025)
Open Access
GLP-1 receptor agonists—another promising therapy for Alport syndrome?
Jan Boeckhaus, Holly Mabillard, John A. Sayer
Journal of Rare Diseases (2025) Vol. 4, Iss. 1
Open Access
Glucagon-like peptide-1 receptor agonists to improve cardiorenal outcomes: data from FLOW and beyond
Labib Imran Faruque, Kevin Yau, David Z.I. Cherney
Current Opinion in Nephrology & Hypertension (2025)
Closed Access
GLP-1 Receptor Agonists for CKD: Remaining Issues or Mission Complete?
Vanja Kosjerina, Peter Rossing
American Journal of Kidney Diseases (2025)
Closed Access
Causal impact of elevated body mass index on diabetic kidney disease: an integrated Mendelian randomization and Global Burden of Disease Study 2021 analysis
Yexin Chen, Dong-sen Hu, Mon-Jyh Lin, et al.
Renal Failure (2025) Vol. 47, Iss. 1
Open Access
The Composite Number Needed to Treat for Semaglutide in Populations with Overweight or Obesity and Established Cardiovascular Disease Without Diabetes
Christopher Lübker, Jigish Bhavsar, Ruben Vale, et al.
Advances in Therapy (2025)
Open Access
On the Frontlines of Cardiovascular-Kidney-Metabolic Syndrome: A Review of GLP-1 and Dual GLP-1/GIP Receptor Agonists in Cardiovascular and Kidney Health
Lavinia Salama, L. G. Sinn
American Journal of Health-System Pharmacy (2025)
Closed Access
Inkretine für CKD-Patienten
Leonie Kraft, Jörg Latus, Moritz Schanz
Deleted Journal (2025)
Closed Access
Page 1 - Next Page

Scroll to top